Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-15

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MPO is conducting this PMCF study to evaluate the safety and efficacy of its EVOLUTION® Total Knee Arthroplasty (TKA) components marketed in the EU. These types of studies are required by regulatory authorities for all devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK

NCT04145401

Knee Osteoarthritis

ENROLLING_BY_INVITATION

EVOLUTION® Revision STEMMED CS Post Market Clinical Follow-up Study Protocol

NCT06142669

Joint Diseases

RECRUITING

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

NCT04816773

Joint Diseases Osteoarthritis Arthritis Knee +1 more

ENROLLING_BY_INVITATION

Post Market Clinical Follow-Up Study for EVOLUTION® BIOFOAM® Tibia and EVOLUTION® CS/CR Porous Femur

NCT04301622

Knee Osteoarthritis Traumatic Arthritis of Knee Avascular Necrosis +3 more

ACTIVE_NOT_RECRUITING

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems

NCT02314702

Joint Disease

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MicroPort Orthopedics Inc. (MPO) currently markets the EVOLUTION® TKA System globally, including in the European Union (EU). As part of the process for gaining approval to market in the EU, MicroPort is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of this system. These types of studies are required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. The objectives of this study are to evaluate component survivorship, cumulative revision rate, functional outcome scores, and subject satisfaction at early, midterm, and long-term follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Joint Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary Total Knee Arthroplasty

Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts

Total Knee Arthroplasty (EVOLUTION®)

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Total Knee Arthroplasty (EVOLUTION®)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EVOLUTION® Total Knee Arthroplasty System with CS Inserts EVOLUTION® CS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be included in the study, subjects must meet all of the following criteria:

* Has previously undergone primary TKA for any of the following:
* non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
* inflammatory degenerative joint disease including rheumatoid arthritis
* correction of functional deformity.
* Subject was implanted with the specified combination of components
* Subject is willing and able to complete required study visits and assessments
* Subject plans to be available through the 10 year postoperative follow-up visit
* Subject is willing to sign the approved Informed Consent document
* Subject must be at least 2 years post TKA prior to informed consent.

Exclusion Criteria

Subjects will be excluded if they meet any of the following criteria:

* Subject was skeletally immature (less than 21 years of age) at time of implantation
* Subject is currently enrolled in another clinical investigation
* Subject is unwilling or unable to sign the Informed Consent document
* Subject has documented substance abuse issues
* Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
* Subject has a body mass index (BMI) of greater than 40
* Subject is currently incarcerated or has impending incarceration

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No